Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Erez's HEM TEST notes 2024 > MCL facts > Flashcards

MCL facts Flashcards

1
Q

Immunophenotype of MCL

A

CD5, CD19, CD20, sIgM/IgD, FMC7, monoclonal kappa/lambda
CD23 negative
strong CYCLIN D1
SOX-11 positive (negative in non-nodal leukemic type)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Incidence MCL

A

1:200K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Median age MCL

A

68-71

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Translocation of MCL

A

T(11:14) Cyclin D1-IgH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In situ MCL

A

Cyclin D1 positive cells, indolent course

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GI involvement at baseline in MCL %

A

40-80%
Endoscopy is not mandatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

MIPI

A

Age
ECOG
LDH
WBC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Other prognostic factors besided MIPI in MCL

A

Blastoid or pleomorphic histology
Ki 67 >30%
p53
KMT2D
Complex karyotype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Good prognostic factors in MCL

A

SOX11 negative
IGHV mutated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

R main benefit in MCL after CIT

A

LyMA trial
3 year main
OS advantage
After R DHAP and HSCT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Benefit of R main in older adults with MCL

A

MCL elderly trial
indefinite main
PFS benefit
other studies had contradicting results

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

BR+i in MCL

A

SHINE trial
PFS advantage but not OS
no PFS advantage in high risk pts
trail was withdrawn!!
PFS2 may be more applicable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Chemo free doublet in 1st line MCL

A

WINDOW-1- phase II Ri
MANGROVE- R zanu
ENRICH- Ri

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Chemo free triplets in 1st line MCL

A

BOVen zanu+ven+ritux (TP53)
AVR, AVO acala+ven+ritux
OAsIs ibrutinib+ven+ritux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

CAR-T in MCL

A

ZUMA2
Phase II
Post chemo immunotherapy and BTKi
Prolongated PFS and OS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Omitting ASCT in MCL

A

May be possible in BTKi Tx pts

17
Q

Approved bi specifics in MCL

A

Glofitamab as 2nd line and above

18
Q

R-CHOP/R-DHAP protocol for MCL ORR

A

LyMA regimen
90% ORR

19
Q

R -MaxiCHOP/R-AraC for MCL

A

Nordic regimen

20
Q

2nd line Tx in MCL

A

BTKi
Phase II
ORR 85%
CR 30-50%

21
Q

Pirtobrutunib in MCL

A

BRUIN trial
Phase II
BTKi pretreated
ORR 50%
DoR 10 months

22
Q

ASCT advantage in MCL

A

PFS not OS
Not prospectivly tested after R-DHAP

23
Q

Less agressive induction Tx in MCL

A

BR (STiL)
VRCAP (OS compared to R CHOP)
R^2

Erez's HEM TEST notes 2024 (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions